Shots:The US FDA has approved Lynkuet for the treatment of mod. to sev. vasomotor symptoms due to menopause based on P-III (OASIS-1, 2, & 3) trials, with commercial availability expected at the start of Nov 2025; MAA is under the EMA’s review  Efficacy was evaluated in OASIS-1 & 2 trials assessing Lynkuet vs PBO…